期刊文献+

272437例原发食管恶性肿瘤患者的组织病理学类型和临床病理特征分析 被引量:7

Clinical characteristics of 272437 patients with different histopathological subtypes of primary esophageal malignant tumors
原文传递
导出
摘要 目的探讨食管常见、少见和罕见原发恶性肿瘤的组织病理学类型及其年龄和性别等临床病理特征。方法本研究共纳入272437例原发食管恶性肿瘤患者,均接受根治性手术治疗。患者临床病理信息均来自省部共建食管癌防治国家重点实验室食管和贲门癌临床诊疗、病理和随访信息数据库(1973年9月至2020年12月)。所有患者均采用世界卫生组织(WHO)食管肿瘤组织病理学诊断和分类标准(2019年)进行诊断和分类。对WHO诊断和分类标准中未标注的食管肿瘤,按照术后病理诊断和类型单独进行分析。采用SPSS 25.0软件对计数资料进行χ2检验,检验标准α=0.05。结果纳入的食管原发恶性肿瘤患者明确病理诊断共32种组织病理学类型,其中10种在WHO分类中未标注。根据其发生频率,分为常见(食管鳞状细胞癌,占97.1%)、少见(食管腺癌,占2.3%)和罕见(主要是食管小细胞癌、恶性黑色素瘤等,占0.6%)3种类型。食管常见、少见和罕见原发恶性肿瘤均以男性多见,其中食管腺癌差异最明显(男∶女,2.67∶1),其次是食管鳞状细胞癌(男∶女,1.78∶1)和罕见恶性肿瘤(男∶女,1.71∶1)。食管常见肿瘤(鳞状细胞癌)以胸中段为主(65.2%),而食管少见肿瘤(腺癌)以胸下段为主(56.8%),罕见肿瘤中恶性黑色素瘤和恶性纤维组织细胞瘤均以胸下段为主(51.7%和66.7%),其余罕见恶性肿瘤以胸中段为主。结论明确病理诊断的32种食管原发恶性肿瘤组织病理学类型中,最常见肿瘤为食管鳞状细胞癌,少见肿瘤为食管腺癌,罕见肿瘤以食管小细胞癌和恶性黑色素瘤为主;均以男性多见;食管常见恶性肿瘤鳞状细胞癌以胸中段为主,而少见肿瘤食管腺癌以胸下段为主,罕见肿瘤中恶性黑色素瘤和恶性纤维组织细胞瘤均以胸下段为主,其余罕见恶性肿瘤以胸中段为主。 Objective To characterize the histopathological subtypes and their clinicopathological parameters of gender and onset age by common,rare and sparse primary esophageal malignant tumors(PEMT).Methods A total of 272437 patients with PEMT were enrolled in this study,and all of the patients were received radical surgery.The clinicopathological information of the patients was obtained from the database established by the State Key Laboratory of Esophageal Cancer Prevention&Treatment from September 1973 to December 2020,which included the clinical treatment,pathological diagnosis and follow-up information of esophagus and gastric cardia cancers.All patients were diagnosed and classified by the criteria of esophageal tumor histopathological diagnosis and classification(2019)of the World Health Organization(WHO).The esophageal tumors,which were not included in the WHO classification,were analyzed separately according to the postoperative pathological diagnosis.Theχ2 test was performed by the SPSS 25.0 software on count data,and the test standardα=0.05.Results A total of 32 histopathological types were identified in the enrolled PEMT patients,of which 10 subtypes were not included in the WHO classification.According to the frequency,PEMT were divided into common(esophageal squamous cell carcinoma,ESCC,accounting for 97.1%),rare(esophageal adenocarcinoma,EAC,accounting for 2.3%)and sparse(mainly esophageal small cell carcinoma,malignant melanoma,etc.,accounting for 0.6%).All the common,rare,and sparse types occurred predominantly in male patients,and the gender difference of rare type was most significant(EAC,male∶female,2.67∶1),followed with common type(ESCC,male∶female,1.78∶1)and sparse type(male∶female,1.71∶1).The common type(ESCC)mainly occurred in the middle thoracic segment(65.2%),while the rare type(EAC)mainly occurred in the lower thoracic segment(56.8%).Among the sparse type,malignant melanoma and malignant fibrous histiocytoma were both predominantly located in the lower thoracic segment(51.7%,66.7%),and the others were mainly in the middle thoracic segment.Conclusion ESCC is the most common type among the 32 histopathological types of PEMT,followed by EAC as the rare type,and esophageal small cell carcinoma and malignant melanoma as the major sparse type,and all of which are mainly occur in male patients.The common type of ESCC mainly occur in the middle thoracic segment,while the rare type of EAC mainly in the lower thoracic segment.The mainly sparse type of malignant melanoma and malignant fibrous histiocytoma predominately occur in the lower thoracic segment,and the remaining sparse types mainly occur in the middle thoracic segment.
作者 王立东 李留玉 宋昕 赵学科 周福有 徐瑞华 刘志才 李爱丽 李吉林 王献增 张立国 朱芳恒 李学民 赵卫星 郭贵周 高文俊 李秀敏 万里新 库建伟 徐全晓 朱富国 纪爱芳 李惠翔 任景丽 周胜理 陈培楠 鲍启德 高社干 杨海军 魏锦昌 毛伟敏 韩占强 常志伟 周英发 韩雪娜 韩文莉 雷玲玲 范宗民 王苒 杨媛啧 吉佳佳 陈瑶 李志强 胡景峰 孙琳 陈亚杰 白合林 尤朵 Wang Lidong;Li Liuyu;Song Xin;Zhao Xueke;Zhou Fuyou;Xu Ruihua;Liu Zhicai;Li Aili;Li Jilin;Wang Xianzeng;Zhang Liguo;Zhu Fangheng;Li Xuemin;Zhao Weixing;Guo Guizhou;Gao Wenjun;Li Xiumin;Wan Lixin;Ku Jianwei;Xu Quanxiao;Zhu Fuguo;Ji Aifang;Li Huixiang;Ren Jingli;Zhou Shengli;Chen Peinan;Bao Qide;Gao Shegan;Yang Haijun;Wei Jinchang;Mao Weimin;Han Zhanqiang;Chang Zhiwei;Zhou Yingfa;Han Xuena;Han Wenli;Lei Lingling;Fan Zongmin;Wang Ran;Yang Yuanze;Ji Jiajia;Chen Yao;Li Zhiqiang;Hu Jingfeng;Sun Lin;Chen Yajie;Bai Helin;You Duo(State Key Laboratory of Esophageal Cancer Prevention&Treatment and Henan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital,Zhengzhou University,Zhengzhou 450052,China;Department of Pathology and Pathophysiology,School of Basic Medical Sciences,Zhengzhou University,Zhengzhou 450001,China;Department of Thoracic Surgery,Anyang Tumor Hospital,Anyang 455000,China;Department of Oncology,Linzhou Tumor Hospital,Linzhou 456550,China;Department of Pathology,Linzhou Esophageal Cancer Hospital,Linzhou 456592,China;Department of Oncology,Linzhou People′s Hospital,Linzhou 456550,China;Department of Thoracic Surgery,Xinxiang Central Hospital,Xinxiang 453000,China;Department of Pathology,Xinxiang Central Hospital,Xinxiang 453000,China;Department of Pathology,Cixian People′s Hospital,Handan 056599,China;Department of Pathology,the First Affiliated Hospital of Xinxiang Medicine University,Xinxiang 453100,China;Xinxiang Key Laboratory for Molecular Therapy of Cancer,Xinxiang Medical University,Xinxiang 453003,China;Department of Oncology,Nanyang Central Hospital,Nanyang 473009,China;Department of Endoscopy,the Second Affiliated Hospital of Nanyang Medical College,Nanyang 473000,China;Department of Oncology,the First People′s Hospital of Nanyang,Nanyang 473002,China;Department of Oncology,the First People′s Hospital of Shangqiu,Shangqiu 476000,China;Department of Clinical Laboratory,the Affiliated Heping Hospital of Changzhi Medical College,Changzhi 046000,China;Department of Pathology,the First Affiliated Hospital,Zhengzhou University,Zhengzhou 450003,China;Department of Pathology,the Second Affiliated Hospital,Zhengzhou University,Zhengzhou 450003,China;Department of Pathology,Henan People′s Hospital,Zhengzhou 450003,China;Department of Thoracic Surgery,Henan Tumor Hospital,Zhengzhou 450003,China;Department of Oncology,Anyang District Hospital,Anyang 455002,China;Department of Oncology,the First Affiliated Hospital,Henan University of Science and Technology,Luoyang 471003,China;Department of Pathology,Anyang Tumor Hospital,Anyang 455000,China;Department of Thoracic Surgery,Linzhou Esophageal Cancer Hospital,Linzhou 456592,China;Department of Thoracic Surgery,Cancer Hospital of the University of Chinese Academy of Sciences,Hangzhou 310005,China;Department of Pathology,Zhenping County People′s Hospital,Nanyang 474250,China;Department of Gastroenterology,the Second Affiliated Hospital,Zhengzhou University,Zhengzhou 450003,China;Department of Gastroenterology,the Third People′s Hospital of Huixian,Huixian 453600,China)
出处 《中华内科杂志》 CAS CSCD 北大核心 2022年第9期1023-1030,共8页 Chinese Journal of Internal Medicine
基金 国家自然科学基金面上项目(81872032) 国家杰出青年科学基金(30025016) 国家高技术研究发展计划(2012AA02A503) 河南省科技重大专项(161100311300)。
关键词 食管肿瘤 肿瘤组织学类型 临床病理 性别 发病年龄 Esophageal neoplasms Neoplasms by histologic type Clinical pathology Gender Age of onset
  • 相关文献

参考文献6

二级参考文献114

共引文献79

同被引文献47

引证文献7

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部